Product Reports Resources Pricing Login Book a demo

Mankind Pharma

Biotech & Life Sciences · New Delhi, India · Founded 1991 · IPO 2023

Quality pharmaceutical formulations and consumer healthcare products at affordable prices

Valuation $14B
Revenue $1.94B
EBITDA $542M
Power Law Thoroughbred$100M+ revenue

Talent graph

Mankind Pharma's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

1 investor on Mankind Pharma's cap table

Sourced from Dealroom's funding history.

Series B+ 1 investor entered at this stage
Chrys Capital

Global footprint

Where Mankind Pharma has talent and traffic

Workforce by country
24 countries with
team presence
🇮🇳 India98.6%
🇳🇵 Nepal0.3%
🇦🇪 United Arab Emirates0.2%
🇺🇸 United States0.2%
🇱🇰 Sri Lanka0.1%
Top 5 of 24 shown
Web traffic by country
61K monthly visits
across markets
🇮🇳 India86.4%
🇺🇸 United States6.1%
🇬🇧 United Kingdom2.6%
🇨🇦 Canada1.6%
🇦🇪 United Arab Emirates1.3%
Top 5 markets shown

Patent intelligence

$23M patent portfolio · 130 active families

Estimated portfolio value
$23M
0.16% of market cap · 305.7× smaller than top peer Janssen Vaccines ($7.1B)
130 active patent families
Where Mankind Pharma innovates Biomedical engineeringCombinatorial chemistryExcipientMedicinal chemistryOrganic chemistry

Where Mankind Pharma concentrates vs peers

Each axis is a top-10 topic across Mankind Pharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Mankind Pharma's 13 investments and acquisitions.

Every disclosed deal where Mankind Pharma appeared as a backer or acquirer, 2021–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

13 deals across Mankind Pharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Mankind Pharma deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Mankind Pharma's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        13 of 13 deals

        Market sentiment

        What the market is saying about Mankind Pharma

        An AI-synthesized read of the highest-engagement posts about Mankind Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Mankind Pharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles